REG - Futura Medical PLC - Block Listing Six Monthly Review

Futura MedicalAnnouncement

31/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe5235Qa&default-theme=true

RNS Number : 5235Q  Futura Medical PLC  31 May 2024

Block Listing Six Monthly Return

31 May 2024

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon,
that specialises in the development and global commercialisation of
innovative and clinically proven sexual health products, makes the following
update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the
AIM Rules for Companies. All figures relate to options over Ordinary Shares of
0.2 pence each (Ordinary Shares).

Date: 31 May 2024

 Name of applicant:                                                                Futura Medical Plc
 Name of scheme(s):                                                                Unapproved Share Option Scheme

                                                                                   Unapproved Share Incentive Scheme

                                                                                   EMI Share Option Scheme

                                                                                   LTIP Scheme
 Period of return:                        From:                                    1 December 2023    To:                31 May 2024
 Balance of unallotted securities under scheme(s) from previous return:            20,782,665
 Plus:  The amount by which the block scheme(s) has been increased since the       USOS: nil
 date of the last return (if any increase has been applied for):

                                                                                   USIS: nil

                                                                                   EMI: nil

                                                                                   LTIP: nil
 Less:  Number of securities issued/allotted under scheme(s) during period:        USOS: nil

                                                                                   USIS: nil

                                                                                   EMI: nil

                                                                                   LTIP: nil

 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        20,782,665
 Number and class of securities originally admitted and the date of admission      USOS Total: 3,882,912

                                                                                   814,424 25 May 2011

                                                                                   1,202,280          8 October 2013

                                                                                   1,466,208          25 May 2017

                                                                                   400,000 30 May 2018

                                                                                   USIS Total: 425,000

                                                                                   425,000 30 November 2018

                                                                                   EMI Total: 8,112,088

                                                                                   1,520,576          25 May 2011

                                                                                   1,467,720          8 October 2013

                                                                                   1,893,792          25 May 2017

                                                                                   790,000 30 May 2018

                                                                                   1,340,000          30 November 2018

                                                                                   1,100,000           2 February 2023

                                                                                   LTIP Total:  15,035,617

                                                                                   4,444,942            2 February 2023

                                                                                   10,590,675          3 November 2023

 

Contacts:

 Futura Medical plc              James Barder               investor.relations@futuramedical.com

                          (mailto:Investor.relations@futuramedical.com)
                                 Chief Executive Officer

                          +44 (0)1483 685 670
                                 Angela Hildreth

                          www.futuramedical.com (http://www.futuramedical.com/)
                                 Finance Director and COO

 Liberum                         Phil Walker                +44 (0)20 3100 2000

 Nominated Adviser               Richard Lindley

 and Broker                      Nikhil Varghese

 Stifel Nicolaus Europe Limited  Alan Selby                 +44 (0)207 710 7600

 Joint Broker                    Ben Maddison

 Alma Strategic Communications   Rebecca Sanders-Hewett     +44 (0)20 3405 0205

                                 Sam Modlin                 futura@almastrategic.com

                                 Will Ellis Hancock

 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health
products, including lead product Eroxon. Our core strength lies in our
research, development and commercialisation of topically delivered gel
formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the
treatment of Erectile Dysfunction ("ED"). The highly differentiated product,
which is the only topical gel treatment for ED available over the counter and
helps men get an erection in ten minutes, addresses significant unmet needs
in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with
approximately half of all men over 40 experiencing ED and 25% of all new
diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer
markets including Haleon in the US, the largest market for ED in the world,
and Cooper Consumer Health in Europe. Eroxon has been nominated for a number
of healthcare industry awards and has won two to-date.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRAMMATMTMJBFI